Immunotherapy using WT1 peptide against recurrent glioblastoma multiforme: A phase I/II study. - Immunotherapy using WT1 peptide against recurrent glioblastoma multiforme.

Cancer Vaccination Therapy Research Network, Department of Immunology, Kochi Medical School0 个研究点目标入组 30 人开始时间: 2009年6月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The following patients must be excluded: 1) Patients with uncontrollable infectious disease (including active Tuberculosis). 2) Patients with severe symptoms (malignant hypertension, severe congestive heart failure, severe colonary insufficiency, Myocardial Infarction within three months lately, terminal phase liver cirrhosis, uncontrollable Diabetes Mellitus, severe Pulmonary Fibrosis, active interstitial pneumonia, etc.). 3) Patients previously treated with Allogeneic bone marrow transplantation. 4) Patients who are pregnant and/or breast feeding, 5) Patients with severe psychiatric disease. 6) Patients who participate in any other clinical trial. 7) Patients who previously participated in this clinical trial. 8) Any patients disqualified by a study physician because of medical, psychological, or any other factors.

发起方

Cancer Vaccination Therapy Research Network, Department of Immunology, Kochi Medical School